ProMIS Neurosciences Files 8-K on Shareholder Vote Matters

TL;DR

ProMIS Neurosciences is holding a shareholder vote on Nov 17, 2025 - big decisions ahead!

AI Summary

ProMIS Neurosciences Inc. filed an 8-K on November 17, 2025, reporting on a submission of matters to a vote of security holders. The company, formerly known as AMORFIX LIFE SCIENCES LTD, is incorporated in Ontario, Canada, and its principal executive offices are located in Toronto.

Why It Matters

This filing indicates a significant event where ProMIS Neurosciences is seeking approval or reporting on decisions made by its security holders, which could impact the company's future direction.

Risk Assessment

Risk Level: medium — Filings related to shareholder votes can introduce uncertainty and potential changes in corporate strategy or governance.

Key Numbers

• 001-41429 — SEC File Number (Identifies the company's filing history with the SEC.)
• 98-0647155 — IRS Employer Identification No. (Tax identification number for the company.)

Key Players & Entities

• ProMIS Neurosciences Inc. (company) — Registrant
• AMORFIX LIFE SCIENCES LTD (company) — Former company name
• November 17, 2025 (date) — Date of earliest event reported
• Toronto, Ontario (location) — Principal executive offices

FAQ

Filing Documents

• pmn-20251117x8k.htm (8-K) — 43KB
• 0001104659-25-113978.txt ( ) — 165KB
• pmn-20251117.xsd (EX-101.SCH) — 3KB
• pmn-20251117_def.xml (EX-101.DEF) — 3KB
• pmn-20251117_lab.xml (EX-101.LAB) — 17KB
• pmn-20251117_pre.xml (EX-101.PRE) — 12KB
• pmn-20251117x8k_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On November 17, 2025, ProMIS Neurosciences Inc. (the " Company ") held a special meeting of shareholders (the " Special Meeting "). The shareholders considered two proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on October 3, 2025. Of the 53,811,110 common shares, no par value per share (the " Common Shares "), outstanding as of the record date and eligible for voting, 24,328,153 Common Shares, or approximately 45.21%, were present or represented by proxy at the Special Meeting. Set forth below are the results of the matters submitted for a vote of shareholders at the Special Meeting. Proposal No. 1: to consider and, if deemed advisable, to pass a special resolution authorizing the filing of articles of amendment to effect a share consolidation of our Common Shares at a ratio ranging from one-for-five up to one-for-twenty-five, to be determined at the discretion of the Board of Directors (the "Board"), and effected, if at all, within one year from the date of the Special Meeting, with such effective date to be determined at the discretion of the Board (" Share Consolidation Proposal "). Votes For Votes Against Abstained Approval of the Share Consolidation Proposal 21,331,321 2,939,187 57,645 Proposal No. 2: In the event there are not sufficient votes in favor of the foregoing proposal and such proposal is not approved by shareholders, to approve the adjournment of the Special Meeting by the Chairperson to a later date no later than November 17, 2025 at 8:00 a.m., Eastern Time, in accordance with the Company's Bylaws, to solicit additional proxies; provided, the Company shall provide updated instructions to attend such adjournment as necessary (the " Adjourment Proposal "). Votes For Votes Against Abstained Approval of the Adjournment Proposal 22,256,277 1,786,586 285,290 There were n

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROMIS NEUROSCIENCES INC. Date: November 19, 2025 By: /s/ Neil Warma Name: Neil Warma Title: Chief Executive Officer